<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03282955</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-1403</org_study_id>
    <nct_id>NCT03282955</nct_id>
  </id_info>
  <brief_title>The HOME Study (HPN With OMEGA-3)</brief_title>
  <acronym>HOME</acronym>
  <official_title>A Randomized, Controlled, Double-blind, Multicenter Clinical Trial on Home Parenteral Nutrition Using an Omega-3 Fatty Acid Enriched MCT/LCT Lipid Emulsion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to investigate safety and tolerability of an Omega-3-FA-enriched
      lipid emulsion in adult patients with chronic intestinal failure in need of long-term HPN. It
      is aimed to show non-inferiority of the lipid emulsion Lipidem (investigational test product)
      in comparison to the lipid emulsion Lipofundin MCT (investigational reference product) with
      regard to liver function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of liver function parameters from baseline to visit 2</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes will be expressed as the sum of the N(0.1)-transformed differences of bilirubin, ALT and AST (visit 2 - baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine transaminase (ALT)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate transaminase (AST)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST/ALT ratio</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase (ALP)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyl transpeptidase (GGT)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cells (WBCs)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cells (RBCs)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (Hb)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International normalized ratio (INR) (if not possible prothrombin time [PT = Quick-value] is accepted)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time (aPTT)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit (Hct)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cloride</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnesium</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphate</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein (HDL)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-density lipoprotein (LDL)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>α-Tocopherol/Vitamin E (facultative if routinely assessed)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acid pattern in plasma and RBCs</measure>
    <time_frame>8 weeks</time_frame>
    <description>Fatty acid pattern in plasma and RBCs, triene:tetraene ratio obtained from fatty acid pattern in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>8 weeks</time_frame>
    <description>Body mass index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Patients Requiring Home Parenteral Nutrition</condition>
  <arm_group>
    <arm_group_label>Lipidem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. lipid emulsion containing fractionated fish oil (n-3 fatty acid triglycerides)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipofundin MCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>i.v. lipid emulsion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipidem</intervention_name>
    <description>Lipoplus i.v. lipid emulsion for parenteral nutrition</description>
    <arm_group_label>Lipidem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipofundin MCT 20%</intervention_name>
    <description>Lipofundin MCT 20% i.v. lipid emulsion for parenteral nutrition</description>
    <arm_group_label>Lipofundin MCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Signed informed consent available

          -  Male or female patients ≥ 18 years of age

          -  Patients with chronic intestinal failure receiving HPN including lipids in whom the
             parenteral macronutrients have not been changed by more than 10% for at least 6 months

          -  Patients receiving ≥ 3.0 g lipids/kg body weight per week

        Exclusion:

          -  Persistent high total bilirubin values in medical history of last 6 months (&gt;
             40µmol/l)

          -  Patients in whom PN was interrupted for longer than 4 continuous weeks in the
             preceding 6 months

          -  Patients with history of cancer and anti-cancer treatment within the last 2 years

          -  Hypersensitivity to egg, fish, peanut or soya-bean protein or to any of the active
             substances or excipients

          -  Patients treated in the past or currently with Teduglutide

          -  Contraindications to investigational products (if available from medical records)
             including:

               -  Severe hyperlipidemia, including severe hypertriglyceridaemia (≥1000 mg/dl or
                  11.4 mmol/l)

               -  Severe coagulopathy

               -  Intrahepatic cholestasis

               -  Severe hepatic insufficiency

               -  Severe renal insufficiency in absence of renal replacement therapy

               -  Acute thromboembolic events

               -  Fat embolism

               -  Aggravating haemorrhagic diatheses

               -  Metabolic acidosis

          -  General contraindications to parenteral nutrition (if available from medical records)
             including:

               -  Unstable circulatory status with vital threat (states of collapse and shock)

               -  Acute phase of cardiac infarction or stroke

               -  Unstable metabolic conditions (e.g. decompensated diabetes mellitus, severe
                  sepsis, coma of unknown origin)

               -  Inadequate cellular oxygen supply

               -  Disturbances of the electrolyte and fluid balance (e.g. hypokalaemia and
                  hypotonic dehydration)

               -  Acute pulmonary edema

               -  Decompensated cardiac insufficiency

          -  Positive test for HIV, Hepatitis B or C (from medical history)

          -  Known or suspected drug or alcohol abuse

          -  Patients who are unwilling or mentally and/or physically unable to adhere to study
             procedures

          -  Participation in another interventional clinical trial in parallel or within three
             months prior to the start of this clinical trial

          -  Any medical condition that in the opinion of the investigator might put the subject at
             risk or interfere with patients participation For women with childbearing potential
             (i.e. females who are not chemically or surgically sterile or females who are not
             post-menopausal)

          -  Women of childbearing potential tested positive on standard pregnancy test (urine
             dipstick)

          -  Lactation

          -  Women of childbearing potential who do not agree to apply adequate contraception

          -  Persons of legal age who are the subject of a legal protection measure or who are
             unable to express their consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Manager</last_name>
    <phone>+495661710</phone>
    <email>studies@bbraun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospices Civiles de Lyon - Centre hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile Chambrier, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Medical and Surgical Science, University of Bologna, Center for Chronic Intestinal Failure, Department of Digestive System, St. Orsola-Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loris Pironi, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geert Wanten, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanley Dudrick`s Memorial Hospital</name>
      <address>
        <city>Skawina</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stanislaw Klek, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny, im. prof. dr W. Orlowskiego, Centrum Medycznego Ksztalcenia Podyplomowego, Oddzial Kliniczny Zywienia i Chirurgii</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacek Sobocki, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

